http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Antiviral Effect of Retro-2.1 against Herpes Simplex Virus Type 2 In Vitro
( Wenwen Dai ),( Yu Wu ),( Jinpeng Bi ),( Jingyu Wang ),( Shuai Wang ),( Wei Kong ),( Julien Barbier ),( Jean-christophe Cintrat ),( Feng Gao ),( Zhengran Jiang ),( Daniel Gillet ),( Weiheng Su ),( Ch 한국미생물생명공학회(구 한국산업미생물학회) 2018 Journal of microbiology and biotechnology Vol.28 No.6
Herpes simplex virus type 2 (HSV-2) infection has been a public health concern worldwide. It is the leading cause of genital herpes and a contributing factor to cervical cancer and human immunodeficiency virus (HIV) infection. No vaccine is available yet for the treatment of HSV-2 infection, and routinely used synthetic nucleoside analogs have led to the emergence of drug resistance. The small molecule Retro-2<sup>cycl</sup> has been reported to be active against several pathogens by acting on intracellular vesicle transport, which also participates in the HSV-2 lifecycle. Here, we showed that Retro-2.1, which is an optimized, more potent derivative of Retro-2<sup>cycl</sup>, could inhibit HSV-2 infection, with 50% inhibitory concentrations of 5.58 μM and 6.35 μM in cytopathic effect inhibition and plaque reduction assays, respectively. The cytotoxicity of Retro-2.1 was relatively low, with a 50% cytotoxicity concentration of 116.5 μM. We also preliminarily identified that Retro-2.1 exerted the antiviral effect against HSV-2 by a dual mechanism of action on virus entry and late stages of infection. Therefore, our study for the first time demonstrated Retro-2.1 as an effective antiviral agent against HSV-2 in vitro with targets distinct from those of nucleoside analogs.